- Tytuł:
- S212: PHASE I STUDY OF YTB323, A CHIMERIC ANTIGEN RECEPTOR (CAR)‐T CELL THERAPY MANUFACTURED USING T‐CHARGE™, IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA.
- Autorzy:
- Źródło:
- HemaSphere; 2022 Supplement 3, Vol. 6, p113-114, 2p
Czasopismo naukowe